ImmuPharma plc (LON:IMM – Get Free Report) shares fell 11.9% on Tuesday . The stock traded as low as GBX 3.21 ($0.04) and last traded at GBX 3.30 ($0.04). 12,256,271 shares changed hands during trading, a decline of 57% from the average session volume of 28,209,365 shares. The stock had previously closed at GBX 3.75 ($0.05).
ImmuPharma Price Performance
The firm has a 50 day moving average price of GBX 1.54 and a 200-day moving average price of GBX 1.68. The firm has a market capitalization of £10.24 million, a price-to-earnings ratio of -246.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Cheap Small-Cap Banks for Dividend Growth Investors
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- Using the MarketBeat Dividend Tax Calculator
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
